Neurocrine Biosciences (NBIX) reported second-quarter 2026 total revenues of $959 million, up 39% from $688 million a year earlier. GAAP net income was $144.4 million, with basic earnings per share of $1.43 and diluted earnings per share of $1.39.
The company raised full-year 2026 INGREZZA net product sales guidance to $2.825 billion to $2.875 billion. Neurocrine also completed its acquisition of Soleno Therapeutics in May 2026 and included VYKAT XR sales from the May 18 closing date.
- Total second-quarter revenue was $959 million, compared with $688 million in the prior-year period.
- INGREZZA net product sales were $716 million, up 15% year over year.
- CRENESSITY net product sales were $184 million.
- VYKAT XR net product sales were $54 million from May 18, 2026, the Soleno acquisition closing date.
- GAAP net income was $144.4 million, compared with $107.5 million a year earlier.
- Cash, cash equivalents and marketable securities totaled approximately $482 million at June 30, 2026.
$NBIX Insider Trading Activity
$NBIX insiders have traded $NBIX stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $NBIX stock by insiders over the last 6 months:
- KEVIN CHARLES GORMAN sold 245,088 shares for an estimated $37,824,872
- JULIE COOKE (Chief Human Resources Officer) has made 0 purchases and 5 sales selling 36,937 shares for an estimated $5,770,235.
- STEPHEN A SHERWIN has made 0 purchases and 5 sales selling 25,000 shares for an estimated $4,132,968.
- INGRID DELAET (Chief Regulatory Officer) has made 0 purchases and 5 sales selling 21,199 shares for an estimated $3,747,947.
- DARIN LIPPOLDT (Chief Legal Officer) has made 0 purchases and 4 sales selling 20,000 shares for an estimated $3,497,506.
- JUDE ONYIA (Chief Scientific Officer) has made 0 purchases and 2 sales selling 22,000 shares for an estimated $3,473,575.
- RICHARD F POPS sold 15,000 shares for an estimated $2,364,760
- LESLIE V NORWALK has made 0 purchases and 2 sales selling 5,060 shares for an estimated $800,672.
- DAVID W. BOYER (Chief Corp. Affairs Officer) sold 3,888 shares for an estimated $609,023
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NBIX Hedge Fund Activity
We have seen 373 institutional investors add shares of $NBIX stock to their portfolio, and 318 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP added 2,075,759 shares (+210.8%) to their portfolio in Q1 2026, for an estimated $273,460,490
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,720,984 shares (-91.9%) from their portfolio in Q1 2026, for an estimated $226,722,432
- BELLEVUE GROUP AG removed 1,698,658 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $223,781,204
- AQR CAPITAL MANAGEMENT LLC added 1,667,261 shares (+51.0%) to their portfolio in Q1 2026, for an estimated $219,644,964
- VESTAL POINT CAPITAL, LP added 1,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $164,675,000
- MILLENNIUM MANAGEMENT LLC added 804,581 shares (+181.7%) to their portfolio in Q1 2026, for an estimated $105,995,500
- BLACKROCK, INC. added 555,010 shares (+4.3%) to their portfolio in Q1 2026, for an estimated $73,117,017
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
